These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

408 related articles for article (PubMed ID: 20584229)

  • 21. [New direct oral anticoagulants and venous thromboprophylaxis].
    Degirmenci SE; Steib A
    Rev Prat; 2013 Sep; 63(7):976-9. PubMed ID: 24167901
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Role of new oral anticoagulants in interventional cardiology].
    Brasselet C; Duval S
    Ann Cardiol Angeiol (Paris); 2012 Dec; 61(6):453-6. PubMed ID: 23102941
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Acute management of bleeding in patients on novel oral anticoagulants.
    Siegal DM; Crowther MA
    Eur Heart J; 2013 Feb; 34(7):489-498b. PubMed ID: 23220847
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacology and safety of new oral anticoagulants: the challenge of bleeding persists.
    Levy JH
    Clin Lab Med; 2014 Sep; 34(3):443-52. PubMed ID: 25168936
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New oral anticoagulants: an emergency department overview.
    Wood P
    Emerg Med Australas; 2013 Dec; 25(6):503-14. PubMed ID: 24224462
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The laboratory and the new oral anticoagulants.
    Tripodi A
    Clin Chem; 2013 Feb; 59(2):353-62. PubMed ID: 23043068
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Beyond warfarin: the new generation of oral anticoagulants and their implications for the management of dental patients.
    Firriolo FJ; Hupp WS
    Oral Surg Oral Med Oral Pathol Oral Radiol; 2012 Apr; 113(4):431-41. PubMed ID: 22668425
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Rivaroxaban, dabigatran and apixaban: new anticoagulants in operative urology].
    John A; Michel MS
    Urologe A; 2014 Jun; 53(6):893-902; quiz 903. PubMed ID: 24845012
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [New oral anticoagulant drugs: dabigatran, rivaroxaban and apixaban. Present and future].
    Dumont B; Faille D; Ajzenberg N
    Med Sci (Paris); 2011 May; 27(5):493-500. PubMed ID: 21609670
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Emergency surgery and trauma in patients treated with the new oral anticoagulants: dabigatran, rivaroxaban, and apixaban.
    Moorman ML; Nash JE; Stabi KL
    J Trauma Acute Care Surg; 2014 Sep; 77(3):486-94; quiz 486-94. PubMed ID: 25159255
    [No Abstract]   [Full Text] [Related]  

  • 31. The new oral anticoagulants: a challenge for hospital formularies.
    Merli GJ
    Hosp Pract (1995); 2012 Aug; 40(3):126-8. PubMed ID: 23086101
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Clinical pharmacological aspects of new oral anticoagulants].
    Haschke M
    Ther Umsch; 2012 Nov; 69(11):657-60. PubMed ID: 23117669
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Bleeding complications under oral anticoagulation].
    Beyer-Westendorf J
    Dtsch Med Wochenschr; 2014 Dec; 139(49):2491-3. PubMed ID: 25376450
    [No Abstract]   [Full Text] [Related]  

  • 34. New oral anticoagulants: will they replace warfarin?
    Little JW
    Oral Surg Oral Med Oral Pathol Oral Radiol; 2012 May; 113(5):575-80. PubMed ID: 22668618
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New oral anticoagulants after acute coronary syndrome.
    Bennaghmouch N; Ten Berg JM
    Best Pract Res Clin Haematol; 2013 Jun; 26(2):141-50. PubMed ID: 23953902
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Implications of new anticoagulants in primary practice.
    Perez A; Eraso LH; Merli GJ
    Int J Clin Pract; 2013 Feb; 67(2):139-56. PubMed ID: 23305476
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Non-vitamin K antagonist oral anticoagulants (NOACs): a view from the laboratory.
    Blann AD
    Br J Biomed Sci; 2014; 71(4):158-67. PubMed ID: 25562993
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New oral anticoagulant agents - general features and outcomes in subsets of patients.
    Schulman S
    Thromb Haemost; 2014 Apr; 111(4):575-82. PubMed ID: 24452881
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Potential net clinical benefit of population-wide implementation of apixaban and dabigatran among European patients with atrial fibrillation. A modelling analysis from the Euro Heart Survey.
    Pisters R; Nieuwlaat R; Lane DA; Crijns HJ; Lip GY
    Thromb Haemost; 2013 Feb; 109(2):328-36. PubMed ID: 23179181
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Anticoagulation in atrial fibrillation: a new era has begun].
    Moser M; Bode C
    Hamostaseologie; 2012; 32(1):37-9. PubMed ID: 22124808
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.